Therapeutic Effects of Melatonin in the Regulation of Ferroptosis: A Review of Current Evidence.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug targets Pub Date : 2024-01-01 DOI:10.2174/0113894501284110240426074746

Mohammad Hossein Pourhanifeh, Azam Hosseinzadeh, Fereshteh Koosha, Russel J Reiter, Saeed Mehrzadi

{"title":"Therapeutic Effects of Melatonin in the Regulation of Ferroptosis: A Review of Current Evidence.","authors":"Mohammad Hossein Pourhanifeh, Azam Hosseinzadeh, Fereshteh Koosha, Russel J Reiter, Saeed Mehrzadi","doi":"10.2174/0113894501284110240426074746","DOIUrl":null,"url":null,"abstract":"<p><p>Ferroptosis is implicated in the pathogenesis of multiple diseases, including neurodegenerative diseases, cardiovascular diseases, kidney pathologies, ischemia-reperfusion injury, and cancer. The current review article highlights the involvement of ferroptosis in traumatic brain injury, acute kidney damage, ethanol-induced liver injury, and PM2.5-induced lung injury. Melatonin, a molecule produced by the pineal gland and many other organs, is well known for its anti- aging, anti-inflammatory, and anticancer properties and is used in the treatment of different diseases. Melatonin's ability to activate anti-ferroptosis pathways including sirtuin (SIRT)6/p- nuclear factor erythroid 2-related factor 2 (Nrf2), Nrf2/ antioxidant responsive element (ARE)/ heme oxygenase (HO-1)/SLC7A11/glutathione peroxidase (GPX4)/ prostaglandin-endoperoxide synthase 2 (PTGS2), extracellular signal-regulated kinase (ERK)/Nrf2, ferroportin (FPN), Hippo/ Yes-associated protein (YAP), Phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT)/ mammalian target of rapamycin (mTOR) and SIRT6/ nuclear receptor coactivator 4 (NCOA4)/ ferritin heavy chain 1 (FTH1) signaling pathways suggests that it could serve as a valuable therapeutic agent for preventing cell death associated with ferroptosis in various diseases. Further research is needed to fully understand the precise mechanisms by which melatonin regulates ferroptosis and its potential as a therapeutic target.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"543-557"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113894501284110240426074746","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Ferroptosis is implicated in the pathogenesis of multiple diseases, including neurodegenerative diseases, cardiovascular diseases, kidney pathologies, ischemia-reperfusion injury, and cancer. The current review article highlights the involvement of ferroptosis in traumatic brain injury, acute kidney damage, ethanol-induced liver injury, and PM2.5-induced lung injury. Melatonin, a molecule produced by the pineal gland and many other organs, is well known for its anti- aging, anti-inflammatory, and anticancer properties and is used in the treatment of different diseases. Melatonin's ability to activate anti-ferroptosis pathways including sirtuin (SIRT)6/p- nuclear factor erythroid 2-related factor 2 (Nrf2), Nrf2/ antioxidant responsive element (ARE)/ heme oxygenase (HO-1)/SLC7A11/glutathione peroxidase (GPX4)/ prostaglandin-endoperoxide synthase 2 (PTGS2), extracellular signal-regulated kinase (ERK)/Nrf2, ferroportin (FPN), Hippo/ Yes-associated protein (YAP), Phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT)/ mammalian target of rapamycin (mTOR) and SIRT6/ nuclear receptor coactivator 4 (NCOA4)/ ferritin heavy chain 1 (FTH1) signaling pathways suggests that it could serve as a valuable therapeutic agent for preventing cell death associated with ferroptosis in various diseases. Further research is needed to fully understand the precise mechanisms by which melatonin regulates ferroptosis and its potential as a therapeutic target.

查看原文本刊更多论文

褪黑激素在调节铁变态反应中的治疗作用：当前证据综述》。

铁蛋白沉积与多种疾病的发病机制有关，包括神经退行性疾病、心血管疾病、肾脏病变、缺血再灌注损伤和癌症。本篇综述文章重点介绍了铁氧化参与创伤性脑损伤、急性肾损伤、乙醇诱导的肝损伤以及 PM2.5 诱导的肺损伤。褪黑素是一种由松果体和许多其他器官产生的分子，以其抗衰老、抗炎和抗癌特性而闻名，并被用于治疗不同的疾病。褪黑素能够激活抗红细胞生成途径，包括sirtuin（SIRT）6/p- 核因子红细胞2相关因子2（Nrf2）、Nrf2/抗氧化反应元件（ARE）/血红素加氧酶（HO-1）/SLC7A11/谷胱甘肽过氧化物酶（GPX4）/前列腺素内过氧化物合成酶 2（PTGS2）、细胞外信号调节激酶（ERK）/Nrf2、铁蛋白（FPN）、这表明，它可以作为一种有价值的治疗药物，防止各种疾病中与铁蛋白沉积相关的细胞死亡。要全面了解褪黑激素调节铁蛋白沉积的确切机制及其作为治疗靶点的潜力，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug targets 医学-药学

CiteScore

6.20

自引率

0.00%

发文量

127

审稿时长

3-8 weeks

期刊介绍： Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.